ClinicalTrials.gg
CompletedNCT04770532ONWARDS 2Updated Dec 15, 2025Results posted

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin

A Phase 3 interventional study of Insulin degludec and Insulin Icodec in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 88 sites in 9 countries. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
526
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
7th of 27
526 · median 84
Started
2021
with 4 others
Phase 3
9 of 27
none open now
Registered
15th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 15th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.

The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily. Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin degludec that participants will have to inject once a day at the same time every day. Which treatment participants get is decided by chance.

The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach.

The study will last for about 8 months. Participants will have 17 clinic visits and 13 phone calls with the study doctor. At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.

Participants will be asked to wear a sensor that measures their blood sugar all the time in 3 periods for a total of 13 weeks (about 3 months) during the study.

Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged above or equal to 18 years at the time of signing .
  • Diagnosed with T2D greater than or equal to 180 days prior to the day of screening.
  • from 7.0-10.0% (53.0 85.8 mmol/mol) both inclusive at screening confirmed by central laboratory analysis.
  • Treated with once daily or twice daily basal insulin (Neutral Protamine Hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL): greater than or equal to 90 days prior to the day of screening with or without any of the following anti-diabetic drugs/regimens with stable doses greater than or equal to 90 days prior to screening:

    • Metformin
    • Sulfonylureas
    • Meglitinides (glinides)
    • DPP-4 inhibitors
    • SGLT2 inhibitors
    • Thiazolidinediones
    • Alpha-glucosidase inhibitors
    • Oral combination products (for the allowed individual oral anti-diabetic drugs)
    • Oral or injectable GLP-1-receptor agonists
  • (BMI) below or equal to 40.0 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Any episodes (as declared by the subject or in the medical records) of diabetic ketoacidosis within 90 days prior to the day of screening.
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening.
  • Chronic heart failure classified as being in Class IV at screening.
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or ).
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
526 participants (actual)

Study arms

  • Experimental
    Insulin icodec

    Insulin icodec + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.

    Drug: Insulin Icodec

  • Active comparator
    Insulin degludec

    Insulin degludec + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.

    Drug: Insulin degludec

Interventions

  • Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily for 26 weeks

  • Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from baseline week 0 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: Baseline (Week 0), Week 26

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    Change in FPG from baseline week 0 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: Baseline (Week 0), Week 26

  2. Percentage of Time in Target-range 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter [mg/dL]) Using Continuous Glucose Monitoring (CGM) System

    The percentage of time in target-range 3.9-10.0 mmol/L (70-180 milligrams per deciliter \[mg/dL\]) using continuous glucose monitoring (CGM) system is presented. Time in target range is defined as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: From week 22 to week 26

  3. Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction

    Change in DTSQs in total treatment satisfaction from baseline (week 0) to week 26 is presented. The DTSQ domain score in total treatment satisfaction was calculated by adding the six item scores of items 1, 4-8. Higher scores indicate higher levels of treatment satisfaction for items 1, 4 -8. For items 2 and 3 a higher score indicates a participant perceived experience of hyperglycaemia and hypoglycaemia. Lower scores indicate a perception of blood glucose levels being unacceptably high (item 2) or low (item 3). The score has a minimum of 0 and a maximum of 36. The outcome data was evaluated based on in-trial observation period. In-trial observation period started at randomisation and ended at the date of: Last direct participant-site contact, withdrawal for participants who withdrew their informed consent, last participant-investigator contact as defined by the investigator for participants who were lost to follow-up and death for participants who died before any of the above.

    Time frame: Baseline (Week 0), Week 26

  4. Number of Severe Hypoglycaemic Episodes (Level 3)

    Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the on-treatment observation period. The on-treatment period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit (V30), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a participant was considered exposed to trial product.

    Time frame: From baseline (week 0) to week 31

  5. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by blood glucose (BG) meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on the on-treatment observation period. The on-treatment period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit (V30), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a participant was considered exposed to trial product.

    Time frame: From baseline (week 0) to week 31

  6. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by blood glucose (BG) meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the in-trial observation period. The on-treatment period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit (V30), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

    Time frame: From baseline (week 0) to week 31

  7. Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System

    Percentage of tiime spent \< 3.0 millimoles per liter (mmol/L) (54 mg/dL) using continuous glucose monitoring (CGM) system is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: From week 22 to week 26

  8. Percentage of Time Spent > 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

    Percentage of time spent \> 10 millimoles per liter (mmol/L) (180 milligrams per deciliter \[mg/dL\]) using continuous glucose monitoring (CGM) system is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: From week 22 to week 26

  9. Mean Weekly Insulin Dose

    Estimated mean weekly insulin dose during the last 2 weeks of treatment (from week 24 to week 26) is presented. The outcome data was evaluated based on the on-treatment observation period. The on-treatment period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit (V30), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a participant was considered exposed to trial product.

    Time frame: From week 24 to week 26

  10. Change in Body Weight

    Change in body weight from baseline week 0 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

    Time frame: Baseline (Week 0), Week 26

07

Results

Posted Feb 20, 2025

Participant flow

The trial was conducted at 71 sites in 9 countries as follows: United States of America (USA) (26), Ukraine (4), Portugal (6), Poland (3), Republic of Korea (7), Japan (9), Germany (6), Bulgaria (4), South Africa (6).

Participant flow — Overall Study
MilestoneInsulin IcodecInsulin Degludec
Started263263
Exposed262263
Full analysis set (fas)263263
Safety analysis set (sas)262263
Completed260258
Not completed35
Withdrew: Withdrawal by subject03
Withdrew: Physician decision10
Withdrew: Death22

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c from baseline week 0 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
Baseline (Week 0), Week 26
Reported as:
Least squares mean · Percentage of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage of HbA1cInsulin IcodecInsulin Degludec
Change in Glycated Haemoglobin (HbA1c)-0.93 ± 0.05-0.71 ± 0.06
Statistical analysis
  • Insulin Icodec vs Insulin Degludec · ANCOVA · p = <0.0001 · Treatment difference: -0.22 · 95% CI -0.37 to -0.08
SecondaryChange in Fasting Plasma Glucose (FPG)

Change in FPG from baseline week 0 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
Baseline (Week 0), Week 26
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change in Fasting Plasma Glucose (FPG)
millimoles per liter (mmol/L)Insulin IcodecInsulin Degludec
Change in Fasting Plasma Glucose (FPG)-1.58 ± 0.12-1.62 ± 0.12
SecondaryPercentage of Time in Target-range 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter [mg/dL]) Using Continuous Glucose Monitoring (CGM) System

The percentage of time in target-range 3.9-10.0 mmol/L (70-180 milligrams per deciliter \[mg/dL\]) using continuous glucose monitoring (CGM) system is presented. Time in target range is defined as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
From week 22 to week 26
Reported as:
Mean · Percentage (%) of time
Percentage of Time in Target-range 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter [mg/dL]) Using Continuous Glucose Monitoring (CGM) System
Percentage (%) of timeInsulin IcodecInsulin Degludec
Percentage of Time in Target-range 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter [mg/dL]) Using Continuous Glucose Monitoring (CGM) System63.13 ± 17.4059.50 ± 18.92
SecondaryChange in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction

Change in DTSQs in total treatment satisfaction from baseline (week 0) to week 26 is presented. The DTSQ domain score in total treatment satisfaction was calculated by adding the six item scores of items 1, 4-8. Higher scores indicate higher levels of treatment satisfaction for items 1, 4 -8. For items 2 and 3 a higher score indicates a participant perceived experience of hyperglycaemia and hypoglycaemia. Lower scores indicate a perception of blood glucose levels being unacceptably high (item 2) or low (item 3). The score has a minimum of 0 and a maximum of 36. The outcome data was evaluated based on in-trial observation period. In-trial observation period started at randomisation and ended at the date of: Last direct participant-site contact, withdrawal for participants who withdrew their informed consent, last participant-investigator contact as defined by the investigator for participants who were lost to follow-up and death for participants who died before any of the above.

Time frame:
Baseline (Week 0), Week 26
Reported as:
Least squares mean · Score on a scale
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction
Score on a scaleInsulin IcodecInsulin Degludec
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction4.22 ± 0.302.96 ± 0.31
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the on-treatment observation period. The on-treatment period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit (V30), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a participant was considered exposed to trial product.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin IcodecInsulin Degludec
Number of Severe Hypoglycaemic Episodes (Level 3)01
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by blood glucose (BG) meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on the on-treatment observation period. The on-treatment period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit (V30), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a participant was considered exposed to trial product.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)
EpisodesInsulin IcodecInsulin Degludec
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)11341
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by blood glucose (BG) meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the in-trial observation period. The on-treatment period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit (V30), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin IcodecInsulin Degludec
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)11342
SecondaryPercentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System

Percentage of tiime spent \< 3.0 millimoles per liter (mmol/L) (54 mg/dL) using continuous glucose monitoring (CGM) system is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
From week 22 to week 26
Reported as:
Mean · Percentage (%) of time
Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System
Percentage (%) of timeInsulin IcodecInsulin Degludec
Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System0.34 ± 0.880.22 ± 0.45
SecondaryPercentage of Time Spent > 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System

Percentage of time spent \> 10 millimoles per liter (mmol/L) (180 milligrams per deciliter \[mg/dL\]) using continuous glucose monitoring (CGM) system is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
From week 22 to week 26
Reported as:
Mean · Percentage (%) of time
Percentage of Time Spent > 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System
Percentage (%) of timeInsulin IcodecInsulin Degludec
Percentage of Time Spent > 10 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System35.52 ± 17.9539.71 ± 19.34
SecondaryMean Weekly Insulin Dose

Estimated mean weekly insulin dose during the last 2 weeks of treatment (from week 24 to week 26) is presented. The outcome data was evaluated based on the on-treatment observation period. The on-treatment period started at the date of first dose of trial product as recorded on the electronic case report form (eCRF), and ended at the first date of any of the following: The end of trial visit (V30), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin (corresponding to 5 weeks after the end of the dosing interval for both treatment arms) and the end-date for the in-trial observation period. The on-treatment period represented the time period in which a participant was considered exposed to trial product.

Time frame:
From week 24 to week 26
Reported as:
Least squares mean · Units of insulin
Mean Weekly Insulin Dose
Units of insulinInsulin IcodecInsulin Degludec
Mean Weekly Insulin Dose267.96 (252.19 to 284.70)244.22 (229.99 to 259.33)
SecondaryChange in Body Weight

Change in body weight from baseline week 0 to week 26 is presented. The outcome data was evaluated based on the in-trial observation period. In-trial observation period started at randomisation and ended at the date of: The last direct participant-site contact, withdrawal for participants who withdrew their informed consent, the last participant-investigator contact as defined by the investigator for participants who were lost to follow-up (i.e., possibly an unscheduled phone visit) and death for participants who died before any of the above.

Time frame:
Baseline (Week 0), Week 26
Reported as:
Least squares mean · Kilograms (kg)
Change in Body Weight
Kilograms (kg)Insulin IcodecInsulin Degludec
Change in Body Weight1.40 ± 0.32-0.30 ± 0.36

Adverse events

Collected over From baseline (Week 0) to Week 31. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Icodec2/262 (0.8%)22/262 (8.4%)50/262 (19.1%)
Insulin Degludec2/263 (0.8%)16/263 (6.1%)39/263 (14.8%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventInsulin IcodecInsulin Degludec
COVID-19Infections and infestations2/2620/263
COVID-19 pneumoniaInfections and infestations2/2620/263
PneumoniaInfections and infestations2/2620/263
ArthritisMusculoskeletal and connective tissue disorders0/2622/263
Acute myocardial infarctionCardiac disorders1/2621/263
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/2620/263
AnaemiaBlood and lymphatic system disorders1/2620/263
Anaphylactic reactionImmune system disorders1/2621/263
CataractEye disorders1/2620/263
Chronic myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2620/263
Most frequent other events
Most frequent other events
EventInsulin IcodecInsulin Degludec
NasopharyngitisInfections and infestations22/26210/263
Diabetic retinopathyEye disorders10/26216/263
DiarrhoeaGastrointestinal disorders14/2629/263
HeadacheNervous system disorders14/2629/263

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)Insulin IcodecInsulin DegludecTotal
Mean62.35 ± 9.7962.60 ± 8.4262.47 ± 9.12
Sex: Female, Male
Sex: Female, Male(Participants)Insulin IcodecInsulin DegludecTotal
Female101123224
Male162140302
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin IcodecInsulin DegludecTotal
Hispanic or Latino161632
Not Hispanic or Latino247247494
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin IcodecInsulin DegludecTotal
American Indian or Alaska Native202
Asian86110196
Native Hawaiian or Other Pacific Islander347
Black or African American111223
White161137298
More than one race000
Unknown or Not Reported000
08

Study locations

88 sites
  • American Clinical Trials
    Buena Park, California 90620, United States
  • Cedars-Sinai Medical Group
    Encino, California 91436, United States
  • Valley Research
    Fresno, California 93720, United States
  • Diabetes/Lipid Mgmt & Res Ctr
    Huntington Beach, California 92648, United States
  • Scripps Whittier Diabetes Inst
    La Jolla, California 92037, United States
  • Clinical Trials Research_Sacramento
    Lincoln, California 95648, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Endo Res Solutions Inc
    Roswell, Georgia 30076, United States
  • Velocity Clin. Res Valparaiso
    Valparaiso, Indiana 46383, United States
  • Four Rivers Clinical Research Inc
    Paducah, Kentucky 42001, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • Ileana J Tandron APMC
    Slidell, Louisiana 70461-4231, United States
  • Endo And Metab Cons
    Rockville, Maryland 20852, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115-5804, United States
  • MassResearch, LLC
    Waltham, Massachusetts 02453, United States
  • Palm Research Center Inc.
    Las Vegas, Nevada 89148, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • Northport VA Med Ctr Northport
    Northport, New York 11768, United States
  • Mountain Diabetes & Endocrine Center
    Asheville, North Carolina 28803, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Amarillo Med Spec LLP
    Amarillo, Texas 79106, United States
  • Osvaldo A. Brusco MD PA
    Corpus Christi, Texas 78414, United States
  • Thyroid, Endocrinology, and Diabetes, PA
    Dallas, Texas 75208, United States
  • Baylr Sctt White Rs Inst, Endo
    Dallas, Texas 75226, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • Diabetes and Thyroid Ctr of FW
    Fort Worth, Texas 76132, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Simcare Medical Research, LLC
    Sugar Land, Texas 77478, United States
  • Hillcrest Family Health Center
    Waco, Texas 76708, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
  • Medical center Medi City 21 OOD
    Kyustendil, 2500, Bulgaria
  • MHAT Med Line Clinic
    Plovdiv, 4000, Bulgaria
  • OCIPSOMCEMD ENDO MED-CONSULT - Dr. Nikolay Botushanov
    Plovdiv, 4002, Bulgaria
  • ASOMCEM - Individual Practice - Dr. Antoanela Slavcheva
    Rousse, 7002, Bulgaria
  • MMA-MHAT Sofia, Clinic of Endocrinology and Metab. Diseases
    Sofia, 1606, Bulgaria
  • UMHAT Sofiamed EAD
    Sofia, 1797, Bulgaria
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Wendisch/Dahl Hamburg (DZHW)
    Hamburg, 22607, Germany
  • Milek, Hohenmölsen
    Hohenmölsen, 06679, Germany
  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
    Münster, 48145, Germany
  • Praxis Dr. med. Wenzl-Bauer
    Rehlingen-Siersburg, 66780, Germany
  • Zentrum für klinische Studien Alexander Segner
    Saint Ingbert-Oberwürzbach, 66386, Germany
  • VvP Kliniken gGmbH Marienhospital Stuttgart - Innere Medizin I
    Stuttgart, 70199, Germany
  • MZM Praxis Drs. Erlinger
    Stuttgart, 70378, Germany
  • Hayashi Diabetes Clinic_Internal Medicine and Diabetes Medicine
    Chigasaki-shi, Kanagawa, Japan 253-0044, Japan
  • Heiwadai Hospital_Internal Medicine
    Miyazaki, Miyazaki 880-0034, Japan
  • Tokuyama clinic_Diabetic internal medicine
    Chiba, 261-0004, Japan
  • Futata Tetsuhiro Clinic Meinohama_Internal medicine
    Fukuoka-shi, Fukuoka, 819-0006, Japan
  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
  • Yuri Ono Clinic
    Sapporo-shi, Hokkaido, 060-0001, Japan
  • Oyama East Clinic_Internal Medicine
    Tochigi, 323-0022, Japan
  • Juntendo University Hospital_Tokyo
    Tokyo, 113-8431, Japan
  • Noritake Clinic
    Ushiku-shi, Ibaraki, 300-1207, Japan
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
    Lodz, 90-338, Poland
  • NZOZ "DiabMed" Poradnia Diabetologiczna
    Poznan, 60-821, Poland
  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
    Warsaw, 02-507, Poland
  • Unidade Local De Saude De Matosinhos E.P.E.
    Senhora Da Hora, Matosinhos, Matosinhos 4464-513, Portugal
  • Unidade Local De Saude De Almada-Seixal E.P.E. - Hospital Garcia de Orta
    Almada, 2805-267, Portugal
  • Unidade Local de Saúde de Coimbra, E.P.E.
    Coimbra, 3000-561, Portugal
  • Unidade Local De Saude De Lisboa Ocidental E.P.E. - Hospital Egas Moniz
    Lisbon, 1349-019, Portugal
  • Unidade Local de Saúde de Santo António, E.P.E
    Porto, 4099-001, Portugal
  • Unidade Local de Saude de Sao Joao E.P.E
    Porto, 4200-319, Portugal
  • Hospital Luz Arrabida, S.A.
    Vila Nova de Gaia, 4400-346, Portugal
  • Greenacres Hospital
    Port Elizabeth, Eastern Cape 6045, South Africa
  • Medi-Clinic Bloemfontein
    Bloemfontein, Free State 9301, South Africa
  • Hemant Makan
    Johannesburg, Gauteng 1827, South Africa
  • Chris Hani Baragwanath Hospital
    Johannesburg, Gauteng 2013, South Africa
  • Centre for Diabetes
    Johannesburg, Gauteng 2198, South Africa
  • Dr A Amod
    Durban, KwaZulu-Natal 4092, South Africa
  • The Catholic University of Korea, ST. Vincent's Hospital
    Suwon, Gyeonggi-do 16247, South Korea
  • Seoul National University Bundang Hospital
    Gyeonggi-do, 13620, South Korea
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Kangbuk Samsung Hospital
    Seoul, 03181, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Nowon Eulji Medical Center, Eulji University
    Seoul, 139-827, South Korea
  • "University Clinic" of Dnipro State Medical University - Endocrinology department
    Dnipro, 49038, Ukraine
  • Department of Medical Service and Rehabilitation of "ARTEM" - day hospital department
    Kyiv, 04053, Ukraine
  • Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
    Kyiv, 04114, Ukraine
  • Ternopil Central District Hospital - Outpatient department
    Ternopil, 46001, Ukraine
09

References and documents

Publications

  • Philis-Tsimikas A, Bajaj HS, Begtrup K, Cailleteau R, Gowda A, Lingvay I, Mathieu C, Russell-Jones D, Rosenstock J. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab. 2023 Feb;25(2):331-341. doi: 10.1111/dom.14871. Epub 2022 Oct 14. PubMed 36106652 ↗
  • Philis-Tsimikas A, Asong M, Franek E, Jia T, Rosenstock J, Stachlewska K, Watada H, Kellerer M. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023 Jun;11(6):414-425. doi: 10.1016/S2213-8587(23)00093-1. Epub 2023 May 3. PubMed 37148899 ↗
  • Philis-Tsimikas A, Krogsdahl Bache J, Fu A, Kellerer M, Salvesen-Sykes K, Bain SC. Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec. Diabetes Ther. 2025 Aug;16(8):1615-1631. doi: 10.1007/s13300-025-01745-4. Epub 2025 Jun 4. PubMed 40465144 ↗
  • Riddell MC, Heller S, Carstensen L, Rocha TMP, Kehlet Watt S, Woo VC. The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5. Diabetologia. 2025 Jul;68(7):1416-1422. doi: 10.1007/s00125-025-06414-6. Epub 2025 Apr 5. PubMed 40186685 ↗
  • Polonsky W, Benamar M, Carstensen L, Davies M, Meller Donatsky A, Franek E, Kellerer M, Philis-Tsimikas A, Goldenberg R. Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1. Diabetes Res Clin Pract. 2024 Nov;217:111885. doi: 10.1016/j.diabres.2024.111885. Epub 2024 Oct 4. PubMed 39368488 ↗
  • Watada H, Asbjornsdottir B, Nishida T, Nishimura R, Yamamoto Y, Yamauchi T, Kadowaki T. Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials. Diabetes Obes Metab. 2024 Dec;26(12):5882-5895. doi: 10.1111/dom.15960. Epub 2024 Sep 30. PubMed 39344833 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2022, 10 months.

Results were first posted in Feb 2025, 3 years after primary completion. A results delay was requested in Jan 2023.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2021
First posted
Feb 25, 2021
StartActual
Mar 5, 2021
Primary completionActual
Jan 27, 2022
CompletionActual
Mar 1, 2022
Results delay requested
Jan 23, 2023
Results first posted
Feb 20, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04770532
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
Mar 5, 2021
Primary completion
Jan 27, 2022
Completion
Mar 1, 2022
Results posted
Feb 20, 2025
Last update
Dec 15, 2025

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion